purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation bmy earnings call period ending december image source motley fool bristol myers squibb bmy q earnings callfeb etcontents prepared remark question answer call participant prepared remark operatorwelcome bristolmyers squibb fourth quarter earnings conference call participant listenonly mode operator instruction today presentation opportunity ask question operator instruction please note event recorded would like turn conference tim power vice president head investor relation please go aheadtim power vice president investor relation well thank good morning everyone thanks joining u morning fourth quarter earnings call joining morning prepared remark chris boerner chief executive officer david elkins chief financial officer also participating today call adam lenkowsky chief commercialization officer samit hirawat chief medical officer head global drug development note posted slide bmscom use follow along chris david remark get started read forwardlooking statement call make statement company future plan prospect constitute forwardlooking statement actual result may differ materially indicated forwardlooking statement result various important factor including discussed company sec filingsshould invest bristol myers squibb right buy stock bristol myers squibb consider motley fool stock advisor analyst team identified believe best stock investor buy bristol myers squibb one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return january forwardlooking statement represent estimate today relied upon representing estimate future date specifically disclaim obligation update forwardlooking statement even estimate change also focus comment nongaap financial measure adjusted exclude certain specified item reconciliation certain nongaap financial measure comparable gaap measure available bmscom hand chris chris boerner chief executive officer thanks tim good morning pleased speaking earnings call first time ceo excited opportunity company continue deliver transformational medicine patient please turn slide q good quarter including strong sale momentum inline new product portfolio growth nearly billion revenue growth across multiple key brand including eliquis opdivo reblozyl opdualag breyanzi camzyos sotyktu also continued generate significant cash flow operation billion quarter hear david minute expect grow business year fourth quarter also achieved important pipeline milestone several key business development transaction strengthen growth profile important time bm know many focused strategy navigate decade importance disciplined execution company writing next chapter bm come opportunity change let take minute tell strategy navigate loes clear focus execution let u go slide see company today look business comprised two portfolio first see legacy portfolio wellestablished product facing headwind ira though portfolio declining expected continue generate strong cash flow enable investment future growth driver second see expanding portfolio growth product many relatively newer market significant expansion potential look portfolio combined exciting pipeline see come together depicted slide think decade see three distinct period nearterm growth period transition period potential sustainable toptier growth plan drive back end decade middle decade focus maximizing opportunity growth portfolio along pipeline execution best position company transition period starting around exposure acute focus shortening transition period much possible accelerating rd program executing product approval launch maintaining pl discipline finally latter part decade around beyond plan deliver sustainable toptier growth portfolio pipeline financial flexibility support opportunity many recognize first two period however latedecade returntogrowth phase le appreciated externally including number important product fully appreciated consensus model today support confidence expanding pipeline recent deal newly launched product strategy minimize transition period coming year maximizing growth back part decade turning slide confidence strategy supported fact compared company successfully navigated similar period clear strength expanding growth portfolio across multiple therapeutic area exciting pipeline differentiated platform continued financial strength invest growth business development momentum recent quarter capitalize strength clear slide october told would strengthen commercial performance q making progress increased investment behind key growth brand camzyos sotyktu reaccelerating growth reblozyl capitalizing launch command indication firstline md effort establish opdualag standard care firstline melanoma driving growth made progress expanding capacity cell therapy particularly setting breyanzi significant expansion year rd delivered important milestone including recharging early stage pipeline inds told would rd day delivering approval augtyro firstline rospositive lung cancer advancing key platform including initiating cd nex study multiple sclerosis cell therapy program showing early important phase data ar ldd prostate asset targeted protein degradation platform importantly active business development specifically diversified oncology portfolio targeted oncology asset krazati prmt recently completed mirati acquisition planned addition differentiated bispecific adc systimmune exciting phase data across tumor including lung breast cancer planned acquisition rayzebio bringing important radiopharmaceutical asset pipeline manufacturing capability announced planned acquisition karuna therapeutic bringing karxt believe transformational medicine patient schizophrenia alzheimers psychosis potentially indication multibilliondollar sale potential looking forward launching medicine closing transaction later year deal add important growth substrate company diversify portfolio long term let u turn slide execution top priority starting commercial focus continuing accelerate performance key growth driver mean ensuring right resourcing investment level across important brand mean best people driving accountability delivering result rd building momentum described coming last quarter highlighted rd day strong pipeline potential deliver ne late need accelerate deliver toptier productivity also taking hard look pipeline prioritize investment project higher return opportunity discontinuing lower priority program opex base told going absorb opex karuna mean need make room asset focusing opex base increase efficiency productivity begun executing across three front look forward updating progress future quarter plan grow business year shown slide david provide much detail guidance minute important perspective getting longterm plan work requires u deliver well short term week ago reaffirmed longterm target date time also said going back historical practice providing mainly annual guidance total company rather productlevel revenue target therefore updating longterm target moving forward mind see growth portfolio strengthening guidance reflects expected topline growth year hand call david would like thank bm colleague effort serving patient enthusiasm embarking next chapter company daviddavid elkins chief financial officer thank chris thank joining call today chris mentioned important time bm embark next chapter transforming portfolio performance reflect continued strong growth inline new product portfolio ongoing erosion revlimid let u get started topline performance slide unless otherwise stated comparison made versus period sale performance growth rate discussed underlying basis excludes impact foreign exchange delivered sale approximately billion reflected growth inline new product portfolio offset unfavorable impact generic entry year saw continued strong demand key inline product eliquis opdivo newer product gained traction respective market turn slide see sale split legacy growth portfolio chris spoke earlier report business move forward tell transition business already well underway legacy growth portfolio growth portfolio delivered approximately growth support strategy chris discussed earlier see legacy portfolio providing solid foundation cash flow generation near term product within growth portfolio grow significance let dive deeper fourth quarter full year sale performance starting oncology portfolio slide pleased robust demand opdivo achieved strong global sale growth year fourth quarter yous sale grew primarily driven increased volume core indication including firstline lung upper gi adjuvant bladder cancer partially offset opdualags growth firstline melanoma quarter yous international market benefited approximately million favorable stocking internationally sale grew led increased demand lung gastric cancer indication expanded reimbursement turning opdualag doubled full year sale standard care treatment firstline melanoma fourth quarter yous sale grew versus prior year sequentially benefiting strong market share position respect sale augtyro fourth quarter launched late november upon yous approval q sale reflect initial wholesaler stocking look forward bringing important medicine patient let u turn cardiovasculars slide eliquis generated billion sale continues oral anticoagulant globally fourth quarter sale grew primarily driven demand yous continue gain market share competitor internationally sale q broadly flat driven generic entry several european market sale camzyos fourth quarter full year strong including million q december st roughly patient commercial drug average adding roughly patient commercial drug per quarter momentum yous camzyos expected continue internationally expect modest nearterm sale contribution based timing reimbursement newly launched market turning hematology portfolio performance slide starting revlimid global sale full year approximately billion looking forward anticipate continued variability revlimid sale quarter quarter based upon historic pattern specialty pharmacy dispensing anticipate additional volume yous generic enter market march continue forecast stepdown revlimid revenue range billion billion year moving reblozyl global sale grew surpassing billion annualized basis first time quarter reblozyl generated sale growth driven strong demand supported broad yous firstline label sale grew yous q internationally reblozyl continues launched different market across globe including recently japan turning cell therapy portfolio starting sale abecma yous continue experience competitive impact ex yous demand remained strong quarter remain focused demonstrating benefit product profile customer anticipation expanded use yous upon potential approval karmma data thirdline plus setting abecma recently approved japan thirdline setting based karmma data last week received positive chmp opinion moving breyanzi global sale doubled year year reflecting strength clinical profile improved manufacturing capacity pleased received fda priority review three expanded indication breyanzi look forward pdufa date march chronic lymphocytic leukemia additional pdufa date may follicular mantle cell lymphoma indication looking year expect see strong sale growth starting second quarter driven improved supply capacity potential new additional indication moving immunology slide global sale zeposia grew million driven increased demand multiple sclerosis ulcerative colitis remain focused driving growth across indication keep mind typical impact yous zeposia sale first quarter due copay assistance commercially insured patient whose benefit reset sotyktu goal continues driving demand broadening access made good progress front fourth quarter fourth quarter sale yous also benefited clinical supply purchase million strip onetime purchase q q showed strong underlying sequential sale growth approximately reflecting good pullthrough cv increased demand going forward way look progress yous commercially paid prescription build volume improve access subject higher rebate something keep mind model sotyktu course adam talk qa portion call today internationally expect sotyktu gain additional country regulatory reimbursement approval time switching gear fourth quarter pl slide covered sale performance let walk nongaap key line item gross margin percentage sale decreased approximately basis point compared prior year due product mix lower hedge settlement gain excluding acquired inprocess rd fourth quarter full year operating expense decreased primarily due timing expense fourth quarter decline partially offset increased investment camzyos sotyktu timing pipeline investment acquired inprocess rd quarter million partially offset licensing income resulting unfavorable net impact eps fourth quarter effective tax rate approximately driven primarily earnings mix overall earnings per share quarter full year moving balance sheet capital allocation slide financial position remains strong approximately billion cash marketable security hand december st generate cash flow operation billion fourth quarter strong financial discipline able invest business expand portfolio maintain strong operating margin pay debt return significant cash shareholder share repurchase dividend past three year returned billion shareholder distribution including dividend increased annually year row know going taking additional debt year finance planned acquisition karuna rayzebio however strong financial position plan utilize cash flow pay debt demonstrated past plan repay approximately billion debt next two year improve leverage profile turning line item guidance let close nongaap guidance slide includes mirati excludes future impact pending transaction systimmune karuna rayzebio providing revenue guidance reported basis well underlying basis assumes currency remains consistent prior year expect revenue increase low singledigit range reflecting confidence growing momentum growth portfolio excluding foreign exchange expect revenue increase low single digit well driving momentum year increasing sale growth portfolio product like opdivo recently launched product said previously expect modest pace growth last year opdivo potential acceleration back half year new indication legacy portfolio includes asset maturing expect strong growth eliquis yous year relates quarterly progression sale reminder product like revlimid pomalyst camzyos keep mind typical impact sale first quarter due patient entering medicare coverage gap early year eliquis coverage gap dynamic work opposite direction expect sale first half year higher second half relates line item guidance year expect gross margin approximately reflects evolution sale mix nonrecurrence hedging gain last year excluding inprocess rd expect total operating expense increase low singledigit range reflecting additional cost mirati reallocation cost efficiency initiative msa continue invest new product launch aligns previous operating margin target least mean remain focused driving operational efficiency across organization including portfolio prioritization enable u invest growth maintaining high productivity expect oie approximately million income reflecting pd royalty stepdown january well financing cost related mirati acquisition project tax rate approximately reflecting increase due nonrecurrence onetime tax benefit occurred third quarter last year plus anticipated impact pillar finally expect deliver nongaap earnings per share within range clarity guidance excludes three pending transaction reminder systimmune expected add million inprocess rd karuna expected dilutive earnings relating financing cost plan absorb opex rayzebio would approximately dilutive earnings half financing half opex report q april update guidance reflect deal closed time move questionandanswer session want thank colleague around world hard work dedication exciting time bm write new chapter maintain singular focus improving growth profile course decade believe focused financial discipline coupled strong cash flow generation key advantage enable u diversify portfolio invest growth opportunity deliver patient investor turn call back tim chris qatim power vice president investor relation first question please reminder obviously busy morning everybody extent keep one question get many people possible would appreciate let u go first question please question answer operatorthe first question come luisa hector berenberg please go aheadluisa hector berenberg capital market analyst audio gap good morning maybe start abecma fda adcomm coming level confidence heading comment label change impacting car t pressure seeing cartitude might evolve thank youchris boerner chief executive officer first samit answer go adamsamit hirawat chief medical officer head global drug development yeah thank luisa question abecma perspective karmma data shared updated data ash last year saw clear driving overall survival curve crossover patient allowance progression disease standard care arm therefore curve benefit therefore see much impact overall survival benefit patient getting confident much looking forward dialogue discussion regulatory authority looking forward getting product patient soon possible second part asked label update fda seeking right car product around cell malignancy treated thousand patient perspective look data see causative relationship car cell therapy term breyanzi abecma continue dialogue regulator well look final wording fda decide let pas adamadam lenkowsky chief commercialization officer thanks luisa question expect growth abecma karmma key catalyst growth year samit said look forward odac reinforce benefit abecma tripleexposed patient population imagine commercial team launchready time also seeing continued strong international performance launch abecma breyanzi number new country year stated seen continued impact additional bcma agent highly competitive market putting pressure abecma growth team squarely focused opening new account expanding site footprint internationally also yous closing gap efficacy perception including solidifying misconception around abecmas efficacy reinforcing abecmas safety profile particularly relates cns neurotoxicity taken together confident abecmas profile looking forward odac confident competitive yeartim power vice president investor relation thanks adam go next question please andreaoperatorthe next question come chris schott jp morgan please go aheadchris schott jpmorgan chase company analyst hi great thanks much question maybe biggerpicture question new launch think new launch billion know giving longerterm target rough framework think sale guess target providing target maybe talk little bit area see maybe le optimistic versus street consensus know quite bit focus trajectory ramp thanks muchchris boerner chief executive officer thanks question chris maybe start quickly turn adam mentioned going providing individual productlevel guidance think alluded met jp morgan three week ago give continue give company line item guidance today see report today going talking additionally growth portfolio going important think business going forward adam want talk new launchesadam lenkowsky chief commercialization officer yeah thanks question chris mean coming good quarter strong foundation growth build upon focused continuing accelerate new product portfolio maximizing launch last four year certainly prioritizing execution new launch adding investment accelerate performance growth portfolio product like camzyos sotyktu breyanzi also seen strong performance reblozyl opdualag also growth product like eliquis opdivo continue contribute significant growth finally readying launch karxt september excited launch product first new treatment decade schizophrenia also brings multibilliondollar opportunity organization adding excited continue drive commercial performance important tim power vice president investor relation great andrea could go next question pleaseoperatorthe next question come chris shibutani goldman sachs please go aheadunknown speaker hi good morning everyone thank taking question charlie chris question subcutaneous opdivo strategy potential launch heard one competitor yesterday potential subcutaneous cpi considering sounded like careful pricing strategy context potential intravenous biosimilars could market time wondering thinking pricing potential subcutaneous opdivo thank youchris boerner chief executive officer adamadam lenkowsky chief commercialization officer yeah thanks charlie question going comment pricing subcu say know announced positive result subcu opdivo study quarter anticipate launch early next year result opportunity potentially benefit thousand patient well next decade subcu opdivo think important thing keep mind remember subcu potential address treatment burden patient physician due le fiveminute infusion time know talked ability convert roughly overall yous opdivo business subcu would expect see franchise endure next decade certainly look forward bringing important formulation patient physicianstim power vice president investor relation let u go next question please andreaoperatorthe next question come andrew baum citi please go aheadandrew baum citi analyst yeah thank question adam rethought use bridge program launch yous following sotyktu experience know topic realistically long think sotyktu start printing revenue combination broader coverage well getting patient bridge thank youchris boerner chief executive officer adamadam lenkowsky chief commercialization officer great thanks andrew let take second question first answer well bridge question sotyktu important brand organization executing plan know shared last year focused two area first driving demand top funnel second securing access course mentioned pulling patient bridge commercial making progress heard david normalize sale excluding clinical trial order net sale increased versus q access critically important highly competitive market drive commercial sale secured esi cigna onestep position add another million life approximately complement cv zerostep position continue year approximately million life actively negotiating payer look forward updating additional progress due course think year really important focus increased paid commercial prescription sotyktu continue build volume new patient going move directly onto sotyktu specialty pharmacy quite frankly become easier improved access well moving patient bridge onto commercial product david talked today q expect see around paid prescription sotyktu also mentioned increase gross net due broader rebating needed secure improved access impact net sale q expect see good momentum growing base paid prescription year plan get roughly double level around prescription q volume momentum offset grosstonet reset q year progress also asked around conversion conversion going exactly expected made good progress shifting patient cv bridge commercial product talked taking two three month patient move bridge commercial result saw sequential growth excluded clinical trial purchase continue drive demand work continue improve moving patient bridge esi cigna win also work secure improved access well make financial sense sotim power vice president investor relation thanks adam andrea let u go next question pleaseoperatorthe next question come seamus fernandez guggenheim security please go aheadseamus fernandez guggenheim partner analyst hi thanks much quick one reblozyl continued strength brand acceleration starting see talk driving incrementally maybe give u little bit sense thinking international opportunity reblozyl particular thankschris boerner chief executive officer adamadam lenkowsky chief commercialization officer yeah seamus thanks question firstline md launch progressing well yous strong demand supported broad label rsagnostic patient population take back know launched late august initially launch saw rapid switch esas reblozyl seeing strength firstline use across rspositive population steadily building momentum rsnegative patient population particularly community setting majority patient treated also ash presentation heard feedback academic community physician recognizing durability response ability remain transfusion independence key feature brand pleased launch know seeing strong sale performance expect continue year reblozyl also approved japan midjanuary seeing know nice uptake expect european approval first half yeartim power vice president investor relation right let u go next question please andreaoperatorthe next question come tim anderson wolfe research please go aheadtim anderson wolfe research analyst thank sotyktu think q mentioned would take longer get step edits wondering current step edits exactly brand patient step otezla primarily humira either brand biosimilar exactlyadam lenkowsky chief commercialization officer yeah tim thank mentioned secured additional access esi cigna onestep position really regardless product could step otezla could step il il agent market important add another million life complement zero step edits cv taken together million life today know continuing actively negotiate payer update additional progress coming monthstim power vice president investor relation go next question please andreaoperatorthe next question come trung huynh ubs please go aheadtrung huynh ubs analyst hi guy thanks taking question ira realized much say negotiation think cm sent initial offer wondering think impact eliquis given patient mix largely skewed toward medicare think could potential uplift could help offset pricing erosion anticipate commercial spillover pricing impactsadam lenkowsky chief commercialization officer yes thanks question take relates ira know expect improvement patient affordability patient outofpocket change patient year next see acutely next year outofpocket max capped patient liability thereafter know broadly though largely expect medicare part design change impact portfolio largely take effect branded revlimid fully eroded relates commercial spillover think important always looked multiple planning scenario including risk spillover also potential opportunity shared around patient affordability push pull change benefit design going continue manage potential spillover risk commercial transparency mfp price september st also today manage book business need continue remain disciplined across commercial payer time payer want include negotiating mix commercial certainly mean agree expect continued strong performance year eliquis yous expect significant growth end tim power vice president investor relation thanks adam let u go next question pleaseoperatorthe next question come geoff meacham bank america please go aheadgeoff meacham bank america merrill lynch analyst hey guy good morning thanks question chris david capital allocation guy deal closing obviously first half year would say balance year pause deal focus integration would boltons still interest trying get sense launch operationally whether newer product product integration could distraction commercially thankschris boerner chief executive officer thanks question jeff take one know discussed previously think capital allocation business development continues top priority u obviously executed number deal toward end last year got stay focused executing deal said certainly going continue interested bringing innovation company make strategic financial sense would characterize bit bolton opportunity point also course continuing look partnership licensing deal well would characterize business development still prioritytim power vice president investor relation thanks chris let u go next question pleaseoperatorthe next question come matt phipps william blair please go aheadmatt phipps william blair company analyst thanks taking question samit wondering could give u sense many sle patient expect treat nex car program year next step phase study straight pivotal sense yet look likechris boerner chief executive officer samitsamit hirawat chief medical officer head global drug development yeah thank question matt look dose escalation phase recall go one patient one patient beginning soon able treat number patient time give number term many patient intend treat time certainly trial remain open want certainly get good understanding efficacy safety profile right dose patient sle advanced disease intend present data later year emerging first trial term next step would engaging data hand regulatory agency term defining trial look like particular case singlearm openlabel study done immunologic malignancy acceptable approach regulator require randomized approach yet come certainly looking forward emergence data presenting later yeartim power vice president investor relation thanks samit let u go next question please andreaoperatorthe next question come steve scala td cowen please go aheadsteve scala td cowen analyst well thank much believe milvexians afib trial right around point bayer stopped factor xi afib trial reassure u event milvexian afib trial progressing expected samit based everything know confident milvexian afib trial underway approaching year would imagine sort look already taken thank youchris boerner chief executive officer samitsamit hirawat chief medical officer head global drug development thank steve question thoughtful always tell trial continuously progressing three trial af secondary stroke prevention ac enrollment going well certainly dmc continues oversee trial indication dmc otherwise continue look data perspective safety well dmc continue look data nothing report time would say one thing though assuming competitor trial failed whatever reason dos picked philosophy actually conduct two welldesigned study picked differential dos atrial fibrillation versus ssp ac reason believe certainly looking forward readout trial tim power vice president investor relation thank samit andrea go next question pleaseoperatorthe next question come terence flynn morgan stanley please go aheadterence flynn morgan stanley analyst great thanks much taking question wondering could elaborate thought breyanzis commercial potential year particularly secondline setting final o data might impact anything seeing respect outpatient treatment breyanzi thank youchris boerner chief executive officer adam samitsamit hirawat chief medical officer head global drug development yeah certainly thank start pas rd always come first commercial start breyanzi certainly looking forward three pdufa date adam mentioned earlier well david remark follicular lymphoma mantle cell lymphoma cll course planning trial lymphoma patient remains high unmet medical need course multiple cell therapy product development talking outofspec continuation discussion continue engage regulatory authority update later date inkling term landing adamadam lenkowsky chief commercialization officer yeah thanks question pleased breyanzis performance quarter saw doubledigit growth quarter quarter also expect continue make good progress breyanzi supported strengthening vector supply fact see supply materialize even q expand support new indication breyanzi starting planned cll indication march breyanzi first cell therapy agent indication samit alluded making good progress reducing turnaround time outofspec drug product capacity move course first half year broad label lbcl three fda priority review first half year breyanzi potential treat broadest array b cell malignancy car indication believe double addressable patient population breyanzi pleased seeing progress making seeing increase outpatient use bestinclass safety profile breyanzi brings expect strong demand growth yeartim power vice president investor relation let u go next question please andreaoperatorthe next question come evan seigerman bmo capital market please go aheadevan seigerman bmo capital market analyst hi guy thank much taking question last week presented initial data androgen receptor liganddirected degrader asco gu hosted event sell side would love speak think important investor analyst pay attention phase asset company large bristolmyers know lot going pipeline focused thing like thank youchris boerner chief executive officer samit start turn adam get feedback kols productsamit hirawat chief medical officer head global drug development yeah thank evan think good question reason believe important u able highlight multifold let start saying remember last year rd day said two platform critical believe continuing progress ar ldd molecule first protein degrader platform go solid tumor wanted absolutely able demonstrate anticipated progressing well showing efficacy manageable safety profile patient lateline prostate cancer saw data psa psa reduction durability truly correlated look data set well literature correlation impacting overall survival truly excited seen thus far course enrolling patient dose optimization phase interaction regulatory authority planning initiating next phase development registration trial within next six month let pas adam comment perspective well adam lenkowsky chief commercialization officer yeah thanks samit evan thanks question excited samit said platform protein degradation relates ar lld prostate cancer diversifies io portfolio even complement recent deal know number kol community feedback coming asco gu presentation tl know enthusiastic profile particularly around efficacy asset durability response asked community physician reassured around safety profile well stating manageable safety profile know enthusiastic moving phase registrational study look forward opportunity treat patient lateline prostate cancertim power vice president investor relation let u go next question please andreaoperatorthe next question come carter gould barclays please go aheadcarter gould barclays analyst great thank good morning thanks taking question adam wanted come back camzyos sort shown pretty steady kind addition sort number patient sort quarter would expect know sort gotten foot launch number would increasing sort know quarter like see launch guess suggests sort gating factor whether logistics whatnot maybe elaborate seeing know whether disagree agree kind framed know whatever extent comment trend going forward thank youchris boerner chief executive officer adamadam lenkowsky chief commercialization officer sure carter thanks question continue make good progress camzyos talked investing behind brand unbranded branded directtoconsumer expect see continued steady consistent growth david mentioned opening remark averaging around patient quarterly basis patient physician feedback continue positive remember patient going treatment long time taking back jp morgan recall chris showed analog camzyos tracking akin strong cv launch case entresto way cardiovascular launch know uptake focused continuing drive breadth top coes continuing expand outside top coes working increase diagnosis rate activating patient via new dtc advertising coupled new launch internationally confident going lead continued sustained growth important brandtim power vice president investor relation let u go next question please andreaoperatorthe next question come mohit bansal well fargo please go aheadunknown speaker hi serena mohit bansal thanks taking question wanted ask phase opdualag readout coming early year firstline lung cancer wondering meaningful think data could considering comparator arm opdivochemo versus opdivoyervoy approved regimen thank youchris boerner chief executive officer samitsamit hirawat chief medical officer head global drug development yeah thank question obviously looking forward seeing data opdualag randomized phase study looking combination opdivo relatlimab plus chemotherapy comparing opdivochemo intent twofold one wanted get contribution component question right away show contribution relatlimab top opdivo chemotherapy number two also wanted plan study go phase appropriate control arm widely used right pembrochemo therefore set dependent course data later quarter year able hear data based data making decision go drugtim power vice president investor relation perfect thanks samit let u go next question pleaseoperatorthe next question come robyn karnauskas truist security please go aheadunknown speaker hey guy thank much taking question inaudible robyn followup question camzyos wondering talk little bit know think recent data competitor might broadly impact landscape hcm obviously drug approved yet see data improving awareness based expect see sort inflection point also talk little bit effort ex yous continue see steady growth sort inflection point based reimbursement reimbursement expect thank youchris boerner chief executive officer samit adamsamit hirawat chief medical officer head global drug development yeah thank question way would look competitor data actually strengthens confidence camzyos within camzyos clinical trial three phase trial read amazing transformational data seen data explorer seen data valor recently readout phase trial japan well replicates result already seen first two trial adam would tell treated thousand patient data also continues showcase efficacy drug well maintains safety drug see data presented realworld setting acc overall safety profile drug general would say camzyos life promise transformational potential patient patient go drug usually want come benefit achieving adamadam lenkowsky chief commercialization officer yes thanks question certainly looked topline data sequoia consistent internal expectation obviously need see data set ultimately see clinically meaningful difference data fact spoke know many tl data shared stated aficamten data appears similar undifferentiated camzyos also course want see broad data set also talked difference pvo clinically meaningful endpoint likely difference due difference patient population across two study assure certainly prepared aficamten come market leading cardiovascular organization maintained consistent view remain leader space also said though know important thing keep mind class see another competitor could net positive help drive awareness patient symptomatic ohcm increase diagnosis rate also really important finally relates expansion outside yous starting see expansion outside yous launched germany prepare launch japan china midyear host market start see sale manifest back end year tim power vice president investor relation right let u go next question please andreaoperatorthe next question come james shin deutsche bank please go aheadjames shin deutsche bank analyst good morning guy thank taking question wanted circle back zeposia adam think mentioned earlier late last year access still improving uc access going improve uniquely year going take little bit time sort like similar situation sotyktu psoriasisadam lenkowsky chief commercialization officer yeah thanks question overall seeing solid continued quarterly yearonyear growth david shared showed growth versus prior year think zeposia really tale two launch m performance among oral competitor solid expect continued share growth growing face declining oral market favor b cell agent continue opportunity continued growth uc know competitive market know making progress volume share increasing focused expanding breadth prescribers continuing position zeposia earlier line treatment opportunity additional indication like crohn disease data readout later year also add know sale zeposia expect see continued growth zeposia patient continue accumulate physician continue gain experience producttim power vice president investor relation great maybe time one two maybe go next question one andreaoperatorok next question akash tewari jefferies please go aheadakash tewari jefferies analyst hey thanks much comment drive confidence alzheimers psychosis trial leading positively color percent patient think able get high dose karxt percent dropout think occur treatment arm adept trial roughly similar seen schizophrenia study thank youchris boerner chief executive officer samitsamit hirawat chief medical officer head global drug development thank question akash look confidence audio gap remains high reason go back first publication xanomeline trial study published think fact look data positive trial tell u mm muscarinic receptor agonist work obvious issue toxicity due peripheral muscarinic agonism seen combination trospium led obviously better outcome saw schizophrenia trial ad psychosis right beginning stage dos tested right hard comment dose utilization would whether patient highest dos early tell get course karuna u continue operate separate company right transaction close able get deeper look future look like talking later date thank youtim power vice president investor relation let u go last one please andreaoperatorthe next question come rajesh kumar hsbc please go aheadrajesh kumar hsbc analyst hi good morning appreciate obviously know give color eliquis price negotiation look margin guidance year assuming made assumption implicit guidance outcome negotiation expect get clarity adjust guidance learnedchris boerner chief executive officer rajesh thanks question try start turn david talk little bit thinking margin correct going able give additional discussion around sit ira eliquis got initial offer going follow process price public september providing additional detail around maybe david talk bit think margin generallydavid elkins chief financial officer yeah overall know guided anticipate gross margin year really driven loe brand coming growth portfolio continues increase obviously help offset longer term gross margin going also said know operating expense grow mid low singledigit range really lot going said karuna going find saving efficiency order cover expense also know adam indicated said opening remark increasing know investment camzyos sotyktu know finding legacy brand refunneling resource said able deliver margin greater year feel confident abouttim power vice president investor relation thanks david think time thank joining call today know busy day hopefully get sense discussion morning exited good momentum capitalize strategy articulated going navigate decade course look forward sharing progress future call close call always team available answer question following today discussion hope good day good weekend thanksoperatoroperator signoff duration minutescall participantstim power vice president investor relationschris boerner chief executive officerdavid elkins chief financial officerluisa hector berenberg capital market analystsamit hirawat chief medical officer head global drug developmentadam lenkowsky chief commercialization officerchris schott jpmorgan chase company analystunknown speakerandrew baum citi analystseamus fernandez guggenheim partner analysttim anderson wolfe research analysttrung huynh ubs analystgeoff meacham bank america merrill lynch analystmatt phipps william blair company analyststeve scala td cowen analystterence flynn morgan stanley analystevan seigerman bmo capital market analystcarter gould barclays analystjames shin deutsche bank analystakash tewari jefferies analystrajesh kumar hsbc analyst bmy analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position recommends bristol myers squibb motley fool disclosure policy